| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Revenue from contract with customer, including assessed tax | - | - | 40,190 | |
| Commercialization revenue | 3,453 | 17,575 | - | |
| Cost of commercialization revenue | 115 | 554 | 7,602 | |
| Research and development expenses | 2,925 | 7,310 | 43,924 | |
| General and administrative expenses | 3,987 | 6,514 | 10,421 | |
| Total costs and operating expenses | 7,027 | 14,378 | 61,947 | |
| Income (loss) from operations | -3,574 | 3,197 | -21,757 | |
| Interest income | 204 | 143 | 459 | |
| Interest expense | 909 | 972 | 1,183 | |
| Other income (expense), net | 4 | 22 | 555 | |
| Total other income (expense), net | -701 | -807 | -169 | |
| Income (loss) before provision for (benefit from) income taxes | -4,275 | 2,390 | -21,926 | |
| Provision for (benefit from) income taxes | 28 | 3 | -17 | |
| Net income (loss) | -4,303 | 2,387 | -21,909 | |
| Unrealized gain (loss) on available-for-sale securities | 2 | 0 | 36 | |
| Comprehensive income (loss) | -4,301 | 2,387 | -21,873 | |
| Earnings per share, basic | -0.32 | 0.2 | -2.93 | |
| Earnings per share, diluted | -0.32 | 0.19 | -2.93 | |
| Weighted average shares outstanding - basic | 13,564,000 | 12,197,000 | 7,466,000 | |
| Weighted average shares outstanding - diluted | 13,564,000 | 12,310,000 | 7,466,000 | |
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)